Cargando…

Association of Lymphocyte-to-Monocyte Ratio With Survival in Advanced Gastric Cancer Patients Treated With Immune Checkpoint Inhibitor

BACKGROUND: Optimal prognostic biomarkers for patients with gastric cancer who received immune checkpoint inhibitor (ICI) are lacking. Inflammatory markers including lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio (PLR), and systemic inflammation index (SII) are easily available. Ho...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yang, Zhang, Cheng, Peng, Zhi, Qi, Changsong, Gong, Jifang, Zhang, Xiaotian, Li, Jian, Shen, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8203902/
https://www.ncbi.nlm.nih.gov/pubmed/34141607
http://dx.doi.org/10.3389/fonc.2021.589022
_version_ 1783708258375041024
author Chen, Yang
Zhang, Cheng
Peng, Zhi
Qi, Changsong
Gong, Jifang
Zhang, Xiaotian
Li, Jian
Shen, Lin
author_facet Chen, Yang
Zhang, Cheng
Peng, Zhi
Qi, Changsong
Gong, Jifang
Zhang, Xiaotian
Li, Jian
Shen, Lin
author_sort Chen, Yang
collection PubMed
description BACKGROUND: Optimal prognostic biomarkers for patients with gastric cancer who received immune checkpoint inhibitor (ICI) are lacking. Inflammatory markers including lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio (PLR), and systemic inflammation index (SII) are easily available. However, its correlation with ICI is unknown in gastric cancer. Here, we evaluated the potential association between LMR, PLR, and SII with clinical outcomes in gastric cancer patients undergoing ICI therapy. METHODS: We examined LMR, PLR, SII at baseline, and 6 (± 2) weeks later in 139 patients received ICI therapy between August 2015 and April 2019 at Peking University Cancer Hospital (Beijing, China). Landmark analysis at 6 weeks was conducted to explore the prognostic value of LMR, PLR, and SII on progress-free survival (PFS), and overall survival (OS). A Cox proportional hazards model was used to compute mortality hazard ratios (HRs) for LMR, adjusting for potential confounders including age, sex, ECOG, tumor location, tumor differentiation, tumor stage, line of therapy, and type of anti-PD-1/PD-L1 therapy. RESULTS: Among 139 patients, 103 (74.1%) were male, median age was 60 years. Median duration of therapy was 6 cycles. We observed that both LMR at baseline and week 6 were independent prognostic factors. Patients with a higher LMR (≥ 3.5) at baseline or week 6 had superior PFS [baseline: HR 0.58, 95% confidence interval (CI): 0.38–0.91; week 6: HR 0.48, 95% CI: 0.29–0.78] and OS (baseline: HR 0.38, 95% CI: 0.24–0.62; week 6: HR 0.52, 95% CI: 0.31–0.88) compared with patients with a lower LMR (< 3.5). Furthermore, for patients with both LMR ≥ 3.5 at baseline and LMR ≥ 3.5 at week 6 were estimated to have much better PFS (HR 0.41, 95% CI: 0.23–0.72) and OS (HR 0.34, 95% CI: 0.18–0.64) than patients with both LMR < 3.5 at baseline and LMR < 3.5 at week 6. CONCLUSIONS: Baseline and early changes in LMR were strongly associated with survival in gastric cancer patients who received ICI therapy, and may serve to identify patients most likely to benefit from ICI.
format Online
Article
Text
id pubmed-8203902
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82039022021-06-16 Association of Lymphocyte-to-Monocyte Ratio With Survival in Advanced Gastric Cancer Patients Treated With Immune Checkpoint Inhibitor Chen, Yang Zhang, Cheng Peng, Zhi Qi, Changsong Gong, Jifang Zhang, Xiaotian Li, Jian Shen, Lin Front Oncol Oncology BACKGROUND: Optimal prognostic biomarkers for patients with gastric cancer who received immune checkpoint inhibitor (ICI) are lacking. Inflammatory markers including lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio (PLR), and systemic inflammation index (SII) are easily available. However, its correlation with ICI is unknown in gastric cancer. Here, we evaluated the potential association between LMR, PLR, and SII with clinical outcomes in gastric cancer patients undergoing ICI therapy. METHODS: We examined LMR, PLR, SII at baseline, and 6 (± 2) weeks later in 139 patients received ICI therapy between August 2015 and April 2019 at Peking University Cancer Hospital (Beijing, China). Landmark analysis at 6 weeks was conducted to explore the prognostic value of LMR, PLR, and SII on progress-free survival (PFS), and overall survival (OS). A Cox proportional hazards model was used to compute mortality hazard ratios (HRs) for LMR, adjusting for potential confounders including age, sex, ECOG, tumor location, tumor differentiation, tumor stage, line of therapy, and type of anti-PD-1/PD-L1 therapy. RESULTS: Among 139 patients, 103 (74.1%) were male, median age was 60 years. Median duration of therapy was 6 cycles. We observed that both LMR at baseline and week 6 were independent prognostic factors. Patients with a higher LMR (≥ 3.5) at baseline or week 6 had superior PFS [baseline: HR 0.58, 95% confidence interval (CI): 0.38–0.91; week 6: HR 0.48, 95% CI: 0.29–0.78] and OS (baseline: HR 0.38, 95% CI: 0.24–0.62; week 6: HR 0.52, 95% CI: 0.31–0.88) compared with patients with a lower LMR (< 3.5). Furthermore, for patients with both LMR ≥ 3.5 at baseline and LMR ≥ 3.5 at week 6 were estimated to have much better PFS (HR 0.41, 95% CI: 0.23–0.72) and OS (HR 0.34, 95% CI: 0.18–0.64) than patients with both LMR < 3.5 at baseline and LMR < 3.5 at week 6. CONCLUSIONS: Baseline and early changes in LMR were strongly associated with survival in gastric cancer patients who received ICI therapy, and may serve to identify patients most likely to benefit from ICI. Frontiers Media S.A. 2021-06-01 /pmc/articles/PMC8203902/ /pubmed/34141607 http://dx.doi.org/10.3389/fonc.2021.589022 Text en Copyright © 2021 Chen, Zhang, Peng, Qi, Gong, Zhang, Li and Shen https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Chen, Yang
Zhang, Cheng
Peng, Zhi
Qi, Changsong
Gong, Jifang
Zhang, Xiaotian
Li, Jian
Shen, Lin
Association of Lymphocyte-to-Monocyte Ratio With Survival in Advanced Gastric Cancer Patients Treated With Immune Checkpoint Inhibitor
title Association of Lymphocyte-to-Monocyte Ratio With Survival in Advanced Gastric Cancer Patients Treated With Immune Checkpoint Inhibitor
title_full Association of Lymphocyte-to-Monocyte Ratio With Survival in Advanced Gastric Cancer Patients Treated With Immune Checkpoint Inhibitor
title_fullStr Association of Lymphocyte-to-Monocyte Ratio With Survival in Advanced Gastric Cancer Patients Treated With Immune Checkpoint Inhibitor
title_full_unstemmed Association of Lymphocyte-to-Monocyte Ratio With Survival in Advanced Gastric Cancer Patients Treated With Immune Checkpoint Inhibitor
title_short Association of Lymphocyte-to-Monocyte Ratio With Survival in Advanced Gastric Cancer Patients Treated With Immune Checkpoint Inhibitor
title_sort association of lymphocyte-to-monocyte ratio with survival in advanced gastric cancer patients treated with immune checkpoint inhibitor
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8203902/
https://www.ncbi.nlm.nih.gov/pubmed/34141607
http://dx.doi.org/10.3389/fonc.2021.589022
work_keys_str_mv AT chenyang associationoflymphocytetomonocyteratiowithsurvivalinadvancedgastriccancerpatientstreatedwithimmunecheckpointinhibitor
AT zhangcheng associationoflymphocytetomonocyteratiowithsurvivalinadvancedgastriccancerpatientstreatedwithimmunecheckpointinhibitor
AT pengzhi associationoflymphocytetomonocyteratiowithsurvivalinadvancedgastriccancerpatientstreatedwithimmunecheckpointinhibitor
AT qichangsong associationoflymphocytetomonocyteratiowithsurvivalinadvancedgastriccancerpatientstreatedwithimmunecheckpointinhibitor
AT gongjifang associationoflymphocytetomonocyteratiowithsurvivalinadvancedgastriccancerpatientstreatedwithimmunecheckpointinhibitor
AT zhangxiaotian associationoflymphocytetomonocyteratiowithsurvivalinadvancedgastriccancerpatientstreatedwithimmunecheckpointinhibitor
AT lijian associationoflymphocytetomonocyteratiowithsurvivalinadvancedgastriccancerpatientstreatedwithimmunecheckpointinhibitor
AT shenlin associationoflymphocytetomonocyteratiowithsurvivalinadvancedgastriccancerpatientstreatedwithimmunecheckpointinhibitor